Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03853486 · ClinicalTrials.gov registry record
ATHN 9: Severe VWD Natural History Study
A clinical trial of Von Willebrand Diseases, sponsored by American Thrombosis and Hemostasis Network.
- Active
- Registry status
- 108
- Enrollment target
- 20
- Study locations
NCT03853486: Active study of Von Willebrand Diseases, sponsored by American Thrombosis and Hemostasis Network.
NCT03853486 is a study of Von Willebrand Diseases that is active but no longer recruiting, run by American Thrombosis and Hemostasis Network. The registered enrollment target is 108 participants, below the 716-participant average among 5 other Von Willebrand Diseases trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03853486, a study of Von Willebrand Diseases, is active but no longer recruiting, sponsored by American Thrombosis and Hemostasis Network.
- ACTIVE NOT RECRUITING
- Registry status
- 108 participants
- Enrollment target
- 20
- Study locations
Study Summary
ATHN 9 is a natural history study to assess the safety of various Von Willebrand Factor (VWF) regimens for different indications (on-demand, surgery and prophylaxis) in adult and pediatric participants with clinically severe congenital VWD.
Primary Outcome
Number of adverse events as measured by EUHASS as well as treatment-emergent side effects of therapy for various Von Willebrand Factor (VWF) regimens for different indications (on-demand, surgery and prophylaxis) in adult and pediatric participants with clinically severe congenital VWD.
Conditions Studied
Study Locations (20)
Michigan
- University of Michigan Hemophilia and Coagulation Disorders - Ann Arbor
- Children's Hospital of Michigan Hemostasis and Thrombosis Center - Detroit
- Michigan State University Center for Bleeding and Clotting Disorders - East Lansing
Pennsylvania
- Pennsylvania Comprehensive Hemophilia and Thrombophilia Program / Hospital of the University of Pennsylvania - Philadelphia
- Hemophilia Center of Western Pennsylvania - Pittsburgh
Tennessee
- University of Tennessee, University Clinical Health (Memphis) - Memphis
- Vanderbilt University Medical Center - Nashville
California
- Center for Inherited Blood Disorders - Orange
Colorado
- University of Colorado Denver Hemophilia and Thrombosis Center - Aurora
Connecticut
- Connecticut Bleeding and Clotting Disorders Center - Farmington
Florida
- University of Florida Hemophilia Treatment Center - Gainesville
Georgia
- Children's Healthcare of Atlanta/Emory - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2019-06-18 |
| Est. Completion | 2026-07-30 |
What the registry record for NCT03853486 still lists
NCT03853486 is an observational study that tracks outcomes without assigning an intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 716-participant average among 5 other Von Willebrand Diseases trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Von Willebrand Diseases appearing as the primary indexed condition, and to 0 interventions.
NCT03853486 names 20 study sites across 16 states, led by Michigan, Pennsylvania, Tennessee.
Frequently Asked Questions
What is clinical trial NCT03853486 about?
NCT03853486 is a clinical study titled "ATHN 9: Severe VWD Natural History Study". ATHN 9 is a natural history study to assess the safety of various Von Willebrand Factor (VWF) regimens for different indications (on-demand, surgery and prophylaxis) in adult and pediatric participants with clinically severe congenital VWD.
What is the current status of trial NCT03853486?
This trial is currently active not recruiting. The enrollment target is 108 participants. The study started on 2019-06-18. Estimated completion is 2026-07-30.
What conditions does trial NCT03853486 study?
This clinical trial studies the following conditions: Von Willebrand Diseases.
Who is sponsoring clinical trial NCT03853486?
This trial is sponsored by American Thrombosis and Hemostasis Network, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03853486 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Von Willebrand Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RECRUITING
-
Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study
RECRUITING
-
Von Willebrand Factor in Pregnancy (VIP) Study
RECRUITING
-
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
RECRUITING · Phase 1
-
Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI